NICE(UK) positive for Kerendia (finerenone) for treating chronic heart failure with preserved or mildly reduced ejection fraction – Bayer

NICE: Finerenone can be used, within its marketing authorisation, as an option to treat symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults.

Why the committee made this recommendation: Usual treatment for heart failure with preserved ejection fraction may include dapagliflozin or empagliflozin, spironolactone and diuretics. In addition to these medicines, usual treatment for heart failure with mildly reduced ejection fraction may also include an angiotensin-converting enzyme inhibitor or angiotensin‑II receptor blocker, and a beta-blocker. People with heart failure may also have related health conditions, and the treatments for these may help with their heart failure. Clinical-trial evidence shows that finerenone reduces the risk of heart-failure events that need an urgent visit to hospital or hospitalisation, compared with placebo. Finerenone may also reduce the risk of dying from cardiovascular or other causes, but the evidence for this is uncertain. Finerenone has not been directly compared in a clinical trial with spironolactone in this population. The results of an indirect comparison and analyses using real-world evidence are uncertain, so it is unclear how well finerenone works compared with spironolactone. The cost-effectiveness estimates are within the range that NICE considers an acceptable use of NHS resources.

So, finerenone can be used.